An Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan and Are Judged by the Investigator to Benefit From Continued QTI571 Treatment

Trial Profile

An Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan and Are Judged by the Investigator to Benefit From Continued QTI571 Treatment

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Imatinib (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 29 May 2017 Status changed from active, no longer recruiting to completed.
    • 21 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 10 Feb 2014 Status changed from not yet recruiting to recruiting according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top